XOMA Royalty announced an agreement to acquire Generation Bio for a fixed cash price per share plus contingent value rights tied to cash balances, lease savings, and potential milestone and royalty payments from Generation Bio’s collaboration with Moderna. The deal will add Generation Bio’s cell‑targeted lipid nanoparticle (ctLNP) delivery platform for nucleic acid therapies to XOMA Royalty’s portfolio and is subject to a tender offer and customary closing conditions.